ADVIA Centaur and Atellica IM HBsAgII

FDA Premarket Approval P110041 S008

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Scale-up and implementation of a common mixing process for all kit bulk reagents

DeviceADVIA Centaur and Atellica IM HBsAgII
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantSIEMENS CORP.
Date Received2020-02-21
Decision Date2020-03-19
PMAP110041
SupplementS008
Product CodeLOM 
Advisory CommitteeMicrobiology
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product No
Applicant Address SIEMENS CORP. 511 Benedict Avenue tarrytown, NY 10591

Supplemental Filings

Supplement NumberDateSupplement Type
P110041Original Filing
S008 2020-02-21 30-day Notice
S007 2019-02-01 30-day Notice
S006 2018-07-19 Real-time Process
S005 2018-04-24 30-day Notice
S004 2017-07-24 Normal 180 Day Track
S003 2015-07-13 Normal 180 Day Track
S002 2015-06-11 30-day Notice
S001 2014-10-02 Real-time Process

NIH GUDID Devices

Device IDPMASupp
00630414599274 P110041 000
00630414578170 P110041 000
00630414599274 P110041 000
00630414578170 P110041 000

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.